SCHEMBL24253457

SCHEMBL24253457

CCc1cn2nccc2nc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
MAPT P10636 1/20 0.33
PCSK9 Q8NBP7 1/20 0.32
PRKAB2 O43741 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA2 P54646 1/20 0.32
PRKAA1 Q13131 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32
PRKAG2 Q9UGJ0 1/20 0.32
PRKAB1 Q9Y478 1/20 0.32
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
DYRK1A Q13627 1/20 0.31
APLNR P35414 1/20 0.31
KCNN3 Q9UGI6 1/20 0.30
KIT P10721 1/20 0.30
DDR1 Q08345 1/20 0.30
PDE4A P27815 1/20 0.30
MGLL Q99685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206565 0.81 KDM4E (0.32) DYRK1AKCNN3
SCHEMBL19545388 0.77 PCSK9 (0.33) PCSK9KCNN3PDE4A
SCHEMBL25064747 0.76 PRKAB2 (0.34) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL25935636 0.74 TSHR (0.46) PDE4A
SCHEMBL31465343 0.73 DYRK1A (0.33) DYRK1A
SCHEMBL6571129 0.73 DYRK1A (0.40) DYRK1A
SCHEMBL24253557 0.72 GABRA1 (0.35) GABRA1GABRB2PCSK9DYRK1A
SCHEMBL15020748 0.68 TDP1 (0.38) MAPT
SCHEMBL10954804 0.67 KCNH2 (0.40) MAPT
SCHEMBL10591743 0.67 TGFBR1 (0.32) KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 GABRA1 2111/4885GABRB2 1261/4885MAPT 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.